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The 5-HT1A agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the
extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2–5 cells. Two 5-HT1A agonists, Repinotan hydrochloride (BAY x 3702)
and 8-OH-DPAT, block caspase-3 activation and apoptosis caused by anoxia/reoxygenation and H2O2 treatment. This is reversed upon
transient expression of dominant negative Ras (N17Ras) and Raf-1 (Raf301), confirming the involvement of Ras and Raf-1 in this 5-HT1A-
R!ERK1/2! caspase-3 pathway. A selective inhibitor of phospholipase Ch (PLCh) (U73122) but not a general protein kinase C (PKC)
inhibitor (GFX) reversed the 5-HT1A-R-mediated ERK1/2 stimulation. However, both GFX and the PKCa and PKCh1 inhibitor Go¨6976
reversed the ERK1/2-mediated inhibition of caspase-3. ERK-dependent activation of only PKCa was observed in immunoprecipitates
obtained from 5-HT1A agonist-treated HN2–5 cells. Finally, transient expression of kinase-negative PKCa eliminated the 8-OH-DPAT-
evoked block on the H2O2-triggered caspase-3 stimulation, establishing PKCa as a link between ERK and caspase-3 (5-HT1A-
R! PLC!ERK1/2! PKCa! caspase-3). Our results elucidate a novel yet general, neuroprotective pathway through which G protein-
coupled receptors could cause inhibition of effector caspases, such as caspase-3.D 2003 Elsevier Science B.V. All rights reserved.Keywords: 5-HT1A receptor; BAY x 3702; ERK1/2; PKC; Caspase-3
1. Introduction More recently, the 5-HT receptor has been shown toThe heptahelical, serotonin 1A receptor couples mainly
to pertussis toxin (PTX)-sensitive G proteins, such as Gi and
Go [1,2]. Among these interactions, the most extensively
studied signaling is in the inhibition of adenylate cyclase
through Gi [3,4]. In addition, agonist binding to this receptor
causes inhibition of N-type Ca-channels and activation of
phospholipase C through distinct pools of G proteins [5,6].0167-4889/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0167-4889(03)00023-5
Abbreviations: MAPK, mitogen activated protein kinase; PI-3K,
phosphoinositol-3-kinase; PTX, pertussis toxin; AcDEVD-AMC, N-
acetyl-Asp-Glu-Val-Asp-(amino-4-methylcoumarin); AcDEVD-CHO, ace-
tyl-Asp-Glu-Val-Asp-aldehyde; AcYVAD-CHO, acetyl-Tyr-Val-Ala-Asp-
aldehyde; Ca/Calmodulin, CaM; PBS, phosphate buffered saline; KRB,
Krebs–Ringer buffer; MEK, MAPK kinase; 5-HT1A-R, serotonin 1A
receptor; PD, PD98059; WAY, WAY100635; ERK, extracellular signal-
regulated kinase; DMSO, dimethyl sulfoxide; GFX, GF109203X (bis-
indolylmaleimide I)
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couple to Gz in Sf9 cells [7]. Serotonin 1A-receptor cou-
pling to such variety of G proteins, however, has a common
denominator—in all these receptor–G protein interactions,
the G protein hg complex is always released, which can
then activate multiple effector molecules or pathways, such
as the phospholipase Ch!ERK1/2 pathway or the PI-3
kinase (PI-3K) pathway [8–11]. By contrast, the G protein
a subunits faithfully couple to one effector molecule—e.g.
Gai couples negatively to adenylate cyclase and Gas couples
positively to adenylate cyclase and Gaq couples positively to
PLCh.
As discussed earlier, in various cell types including
neurons, agonist-stimulated release of the G protein hg
complex results in the activation of ERK1/2 enzymes,
which are members of the mitogen-activated protein kinase
(MAPK) family [10–12]. In this pathway, termed MAP
kinase pathway, activation of multiple signaling proteins
could precede the stimulation of the key enzymes ERK1/2,
which finally regulates many important cellular events, such
as mitosis or survival. Our earlier studies have demonstrateded.
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regulation of the MAP kinase pathway, which results in an
inhibition of the proapoptotic, cysteinyl aspartate-specific
protease, caspase-3 [13].
Mitochondrial impairment caused by diverse types of
tissue insults leads to apoptosis through a generally accepted
pathway, which involves the release of cytochrome c from
the impaired mitochondria, its association with the apopto-
sis-activating factor Apaf-1 and caspase-9, and subsequent
partial activation of caspase-9 [14–17]. The partially acti-
vated caspase-9 undergoes autocatalytic cleavage to yield
fully active caspase-9, which proteolytically activates the
downstream caspase, caspase-3. Therefore, inhibition of this
post-mitochondrial pathway is expected to cause attenuation
of apoptosis caused by diverse conditions, such as anoxia/
reoxygenation, neurodegenerative diseases, or excitotoxicity
triggered by various conditions of neuronal injury, all of
which are known to work through mitochondrial impair-
ment. Earlier studies have shown that signaling from growth
factor receptors can cause inhibition of apoptosis through
PI-3K-mediated activation of Akt, which exerts its kinase
activity to inhibit either the proapoptotic mitochondrial
protein Bad [17] or the proapoptotic protease caspase-9
[16]. By contrast, our previous studies have shown that a G
protein-coupled receptor, the 5-HT1A receptor, causes inhib-
ition of caspase-3 and apoptosis by stimulating a novel, PI-
3K-independent pathway in the hippocampal neuron-
derived HN2–5 cells [11].
As mentioned earlier, in the circuitry of such complex
mechanisms, caspase-3 is clearly the common downstream
protease that has to be somehow inhibited to cause suppres-
sion of apoptosis. Since many conditions of neural insult and
degeneration culminate in the activation of caspase-3, the 5-
HT1A-R-mediated inhibition of caspase-3 could be used as a
general tool to prevent neuronal apoptosis. This study estab-
lishes PKCa as a novel link between the MAP kinase path-
way and caspase-3 and also introduces a measurable effect
(readout), such as the 5-HT1A receptor-evoked caspase-3
inhibition. Such a readout could also be used to study the
connectivity and hierarchy of the upstream members of the G
protein-coupled receptor-activated MAPK cascade, such as
the kinases like Src or Pyk2, which often connect G protein-
coupled receptors to the MAPK pathway.2. Materials and methods
The anti-active MAPK antibody was obtained from New
England Biolabs (MA), and the ERK2 and other antibo-
dies were obtained from Santa Cruz Biotechnology (CA).
The vectors pZipneo, pZipneoN17Ras and pNMC,
pNMCRaf301 were obtained as kind gifts from D. Foster
(Hunter College, CUNY) and S. Gutkind (NIH), respec-
tively. In immunoblotting analysis, the protein bands were
detected by enhanced chemiluminescence using the Super
Signal kit from Pierce (IL). The caspase substrate, acetyl-DEVD-(amino-4-methylcoumarin) (AcDEVD-AMC), the
caspase inhibitor, acetyl-DEVD-aldehyde (AcDEVD-
CHO) as well as PTX, WAY100635, and 8-OH-DPAT were
obtained from Sigma/RBI. bis-indolylmaleimide I (GFX),
Go¨6976, U73122 (a PLCh inhibitor) and PD98059 (an
MEK inhibitor) were obtained from Calbiochem (CA).
Repinotan hydrochloride (BAY x 3702) was obtained from
Bayer Corporation (CT). PBS denotes phosphate-buffered
saline.
2.1. Cell culture and anoxia
The mouse hippocampal neuron-derived HN2–5 cells
were cultured to about 70–80% confluence in DMEM
containing 10% fetal bovine serum and penicillin–strepto-
mycin in poly-L-lysine-coated plates and then differentiated
by 16 h (overnight) treatment with either phosphate-free
Krebs–Ringer buffer (KRB) (25 mM HEPES, 20 mM
glucose, 5 mM KCl, 1.28 mM CaCl2, 1.2 mM MgCl2,
145 mM NaCl, pH 7.4) or 5 AM retinoic acid in DMEM
containing 1% fetal bovine serum for 24 h. Both processes
confer to the cells neuronal morphology and strong immu-
noreactivity to the neurofilament protein-antibody SMI33
[18]. For both MAPK as well as caspase assays, cells in 10
cm plates were used. Following differentiation, the medium
was changed to serum-free DMEM, supplemented with
drugs (8-OH-DPAT, BAY x 3702, antagonists, inhibitors,
etc.), and then, for caspase assays, the cells were subjected
to anoxia as described in our previous report [11]. Prior to
caspase assays, differentiated HN2–5 cells were subjected
to 6 h anoxia followed by 16 h of reoxygenation.
2.2. MAPK assays
For MAP kinase (ERK2) assays, confluent, 10 cm plates
of HN2–5 cells were differentiated overnight in KRB, the
medium changed to serum-free DMEM followed by drug
treatment as described in the figure legends, medium aspi-
rated and cells lysed in RIPA buffer (PBS containing 1%
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.5 mM
Na3VO4 plus freshly added protease inhibitor cocktail;
Boehringer), immunoprecipitated using 1 Ag/ml of MAPK
(ERK2) antibody (polyclonal, Santa Cruz) and protein A-
sepharose, immunoprecipitate resolved on a 7–16% gra-
dient acrylamide gel, proteins transferred to nitrocellulose
membrane, blocked in 5% solution of dry milk and then
probed using a monoclonal, phospho-MAPK (P-MAPK)
specific (anti-active) antibody at 1:1000 dilution and then
with horseradish peroxidase-labeled anti-mouse IgG
(1:1000). Following probing with P-MAPK antibody, the
blot was stripped by incubating for 1 h at room temperature
in 0.2 M glycine (pH 2.5), and then blocked in 5% dry milk
and reprobed with ERK2 antibody (1:500). The ERK2
bands were used for normalization to confirm that the
increase in P-MAPK bands was not due to an increase in
the amount of ERK2 protein.
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Controlled treatment of cells with the membrane-perme-
able dye HOECHST33342 has been shown to effectively
stain apoptotic nuclei and detect chromatin condensation
[19,20]. HN2–5 cells were transfected with control vectors
(pZipneo and pNMC) and those harboring the dominant
negative mutants of Ras (N17Ras) and Raf-1 (Raf301),
differentiated, treated with the agonist, and then subjected
to hypoxia and reoxygenation. Following this the cells were
fixed and permeabilized and then assessed for chromatin
condensation and disintegration of the nucleus by Hoechst
staining [19]. A 1 AM concentration of HOECHST33342
was used to label the cells for 15 min, following which the
dye was washed out with 10 mM PBS and then pictures shot
using a 360 nm excitation/420 nm emission filter. The
apoptotic cells were identified by their disintegrated nuclear
structure and counted to assess the proportion of healthy and
apoptotic cells in multiple fields.
2.4. Caspase-3 assay using a fluorescent substrate
Caspase assays were performed using monolayers of
HN2–5 cells at 80% confluence. Cell lysates were prepared
from hydrogen peroxide-treated or normoxic and anoxic cell
pellets obtained after two washes with ice-cold PBS. Cells
were next lysed in 0.5 ml Yama buffer (10 mM HEPES pH
7.5, 142 nM KCl, 1 mM EGTA, 1 mM DTT, 0.2% NP-40,
0.1 mM PMSF) [21]. Each sample was homogenized with a
Potter Elvehjem homogenizer and then ultracentrifuged at
100,000 g for 5 min. The supernatant obtained was
assayed for protein concentration, which was adjusted to 2
Ag/Al and then an aliquot containing 300 Ag protein was
added to each well of a 96-well plate. This was followed by
the addition of 1.5 Al of 10 mM stock AcDEVD-AMC in
oxygen-free water (final concentration, 100 AM). The
released fluorescence (due to the fluorescent group, AMC,
which is cleaved by the caspases) was monitored after 30-
min incubation using a fluorescence plate reader set at
excitation wavelength 360 nm and emission wavelength
460 nm. Results from multiple caspase assays, each per-
formed with triplicate samples, were combined after conver-
sion into percentage of control caspase activity. Statistical
analysis and determination of P values were carried out using
Student’s t-test.
2.5. Protein kinase C (PKC) enzyme assays
Differentiated HN2–5 cells were treated for 30 min with
1 AM phorbol-myristate (PMA—a positive control), carrier
or 1 AM 8-OH-DPAT in the absence and presence of 25 AM
PD98059, following which the cells were lysed in RIPA
buffer as described in MAPK assays. PKCa and PKCh
were immunoprecipitated from the cell lysates using the
respective antibodies (Santa Cruz). The immunoprecipitates
were washed thoroughly, and then resuspended in 10 Al
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Kit. This suspension was supplemented on ice with 15 Al of
a pre-mixed reaction mixture containing equal volumes of
5 reaction buffer, 5 activator solution (sonicated in a
bath sonicator prior to addition), PKC substrate which also
contained 5 ACi/tube of AT[g-32P]. The final volume with
the protein A-sepharose beads was 30 Al. The tubes were
vortexed and then incubated at 30 jC for 30 min, followed
by microcentrifugation and transfer of 25 Al of the super-
natant to SpinZyme columns. The columns were microcen-
trifuged to elute the aqueous phase. The non-phosphorylated
peptide was next washed off by addition of 250 Al of
Phosphopeptide Binding Buffer (provided in the kit), incu-
bation for 3 min, followed by centrifugation for 1 min at
6000 rpm. This procedure was repeated once for a total
wash of 500 Al, and then the column was placed in a fresh
tube before elution of the phosphopeptide adhering to the
column. For the elution, 250 Al of Phosphopeptide Elution
Buffer (provided in the kit) was applied to the column,
followed by incubation for 3 min and centrifugal elution.
This process was repeated once to obtain a total elution
volume of 500 Al. Next, 20 Al of each eluate was mixed with
3 ml of scintillation fluid and subjected to scintillation
counting using a Beckman scintillation counter.
2.6. Transfection of PKCa vectors and pEGFPC1 into
HN2–5 cells
pEGFPC1 (2 Ag) alone or 1 Ag each of pEGFPC1 and
SRDpkcaKN or pEGFPC1 and SRDpkcaWTwere cotrans-
fected into HN2–5 cells in 24-well plates [22,23]. Trans-
fection was carried out using the SuperFect Transfection kit
from Qiagen Inc., optimized for transfection of HN2–5 cells
in 24-well plate without pre-plating. The cells (1105 per
well) were allowed to settle and attach in the wells for 5 h
with the transfection complex containing 2 Ag of total DNA
and 5 Al of SuperFect reagent. Medium was then changed to
the normal growth medium (10% fetal bovine serum and 1%
penicillin–streptomycin in DMEM) and cells were allowed
to recover for 19–24 h before differentiation. Differentiation
was carried out in 5 AM retinoic acid in 1% fetal bovine
serum containing DMEM for 24 h, following which the
medium was changed to serum-free DMEM and appropriate
wells were treated with carrier or 8-OH-DPAT in the
absence or presence of 25 AM PD98059. H2O2 (200 AM)
was added and the cells were incubated for 16 h in a tissue
culture incubator as described in the following section.
2.7. Hydrogen peroxide treatment and caspase assays of
cells
In all experiments, differentiated HN2–5 cells were used.
Hydrogen peroxide was added from a freshly diluted and
sterile filtered stock solution in serum-free DMEM. Typi-
cally, hydrogen peroxide treatment was carried out for 16 h
before analyzing caspase-3 activity using either a fluores-
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try. For the fluorescent substrate-based assays, HN2–5 cells
grown in 10 cm plates to 70–80% confluence were differ-
entiated and then subjected to H2O2 treatment in serum-free
DMEM. Subsequently, the cells were pelleted down and
subjected to caspase assays as described above.
2.8. Immunostaining to assess caspase-3 activation
In experiments requiring immunostaining, the cells were
grown in 24-well plates, transfected as described above,
differentiated, and then subjected to 200 AM hydrogen
peroxide treatment for 16 h. Subsequently, the cells were
fixed in freshly prepared 3% paraformaldehyde for 30 min at
room temperature, washed two times with PBS, and then
blocked in PBS containing 2% bovine serum albumin
(Fraction V), 2% normal goat serum and 0.4% Triton X-
100 for 1 h at room temperature. Next, the blocking solution
was replaced with 1j antibody (CM1) diluted 1:3000 in
blocking solution. After overnight treatment at 4 jC, the cells
were washed three times with wash buffer (0.2% Tween-20
in PBS) at room temperature and then incubated with the 2j
antibody (goat anti-rabbit IgG-Alexa Fluor 568) (1:2500) in
blocking solution for 1 h at room temperature. After three
washes with the wash buffer and then once with PBS, the
cells were visualized by fluorescence microscopy using
filters with emission wavelengths of 580 nm (for Alexa
Fluor 568) and 510 nm (for green fluorescent protein).
2.9. Statistical analysis
After comparing multiple data sets, results were obtained
as average (F S.D.), and ‘‘P’’ values were obtained using
Student’s t-test.3. Results
3.1. The peak of 5-HT1A-R-mediated activation of ERK1/2
occurs after 30 min of treatment with 100 nm BAY x 3702
Our earlier studies had established the time of optimal
activation of ERK1/2 in 8-OH-DPAT-treated HN2–5 cells.Fig. 1. (a) Time course of BAY x 3702-evoked ERK2 stimulation. Differentiated H
periods. (b) Extended time course. The control was carrier-treated for 3 h, wherea
3702 (1 AM). (c) Dose dependence for BAY x 3702-evoked ERK2 stimulation. La
of BAY x 3702: 5 pM (lane 2), 1 nM (lane 3), 100 nM (lane 4), and 1 AM (laneSimilar analysis of BAY x 3702-elicited ERK1/2 activation
revealed a prominent increase in 5 min of agonist treatment,
however, as observed for 8-OH-DPAT, the BAY x 3702-
elicited ERK1/2 stimulation also reached a maximum in 30
min. However, following this, it decreased dramatically to
virtually basal levels in 3 h (Fig. 1a and b). This is different
from the prolonged activation of ERK observed in 8-OH-
DPAT-treated HN2–5 cells [11] and could be attributed to
the lesser chemical stability of BAY x 3702 in aqueous
solutions. Dose–response analysis revealed that BAY x
3702-triggered ERK1/2 activation was quite significant
even at 1 nM agonist concentration (Fig. 1c). Similar to
the dose– response curve of 8-OH-DPAT, the ERK1/2
stimulation reached a maximum at 100 nM BAY x 3702
and then remained unchanged up to at least 1 AM.
The 5-HT1A-R-mediated ERK1/2 stimulation was not
affected by the PI-3K inhibitor wortmannin (Fig. 2a, lane
5) but was eliminated in the presence of PD98059 (Fig. 2a,
lane 6), which inhibits MEK, the factor immediately
upstream of ERK1/2 in the MAP kinase pathway [24,25].
This is an important difference from the protective pathways
stimulated by other G protein-coupled receptors, which have
been shown to involve PI-3K [25]. The non-involvement of
PI-3K and the involvement of ERK1/2 in the 5-HT1A-R-
mediated inhibition of apoptosis had also been observed in
our earlier studies [11].
Agonist stimulation of the 5-HT1A receptor also causes a
simultaneous increase in intracellular inositol phosphates,
which is a direct measure of PLC activity [11]. Thus, there
was a possibility that this increased PLC activity was
essential for the observed activation of ERK1/2, and this
is supported by earlier studies confirming that ERK stim-
ulation by other G protein-coupled receptors requires acti-
vation of PLCh upstream of Ras [12]. Elimination of the 5-
HT1A-R mediated activation of both ERK1/2 (Fig. 2a) and
inhibition of caspase-3 (Fig. 2b and c) by the PLCh
inhibitor U73122 confirmed the involvement of PLCh
upstream of ERK1/2 [12]. Activation of PLC results in an
increase in intracellular calcium concentration, which causes
activation of PKC. PKC is known to phosphorylate and
activate the signaling protein Raf-1, which stimulates
ERK1/2 via the signaling protein MEK [24]. Therefore, a
PKC isozyme could relay the signal from the activatedN2–5 cells were treated with BAY x 3702 (100 nM) for the indicated time
s the other samples were treated for the indicated time periods with BAY x
nes: 1, control; 2–5, treatment for 30 min with the following concentrations
5). Data shown represent two independent experiments.
Fig. 2. The 5-HT1A agonist-activated MAPK pathway causes a PKC-dependent caspase-3 inhibition, but PKC is not involved in the activation of ERK1/2.
Differentiated HN2–5 cells were treated for 30 min with carrier or 8-OH-DPAT (1 AM) (D) or BAY x 3702 (1 AM) (B) in the absence and presence of GFX (2
AM) (GFX), or PD98059 (25 AM) (PD), WAY100635 (1 AM) (WAY), or U73122 (1 AM) (U). (a) Differentiated HN2–5 cells were treated for 30 min with
either carrier (lane 1), or 8-OH-DPAT (1 AM) (lane 2), or BAY x 3702 (1 AM) in the absence (lane 3) or presence of WAY100635 (1 AM) (lane 4), wortmannin
(0.1 AM) (lane 5), PD98059 (25 AM) (lane 6), GFX (lane 7), or U73122 (1 AM) (lane 8). In a separate set, the cells were treated with 1 AM U73122 alone (lane
9). Next, the cells were lysed and subjected to immunoprecipitation using an ERK1/2 antibody followed by Western blotting using an anti-active ERK1/2
antibody. In a separate set of experiments, cells were subjected to 6 h hypoxia and 16 h reoxygenation, following which cell lysates were either (b) subjected to
caspase assay or (c) analyzed by Western blotting using the anti-active caspase-3 antibody (CM1). Decreased presence of the 17 kDa fragment of active
caspase-3 indicates inhibition of caspase-3 activity. Data presented (a) are the mean (F S.D.) of three independent experiments performed with triplicate
samples. Results are representative of three independent experiments. Normalized intensities of bands shown in (a) and (b) are graphically shown.
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GFX (2 AM) did not affect the BAY x 3702-evoked ERK1/2
activation (Fig. 2a, lane 7). However, as shown in Fig. 2b
and c, GFX did indeed block signaling downstream of
ERK1/2 where PKC could be involved (explained below).
Results presented in Fig. 2a elucidate that the cytoprotec-
tive, 5-HT1A receptor-mediated activation of ERK1/2 occurs
not through a PKC–Raf-1 pathway, but most probably
through a Ras!Raf-1!MEK!ERK1/2 cascade as
reported earlier for the same receptor in non-neural cells
[10].Although data presented in Fig. 1 demonstrate that BAY
x 3702 causes ERK1/2 activation in HN2–5 cells, it was
essential to test if BAY x 3702 affords ERK1/2-mediated
caspase-3 inhibition as 8-OH-DPAT does in HN2–5 cells
[11]. As shown in Fig. 2b and c, BAY x 3702 was even
more effective than 8-OH-DPAT in causing an ERK1/2-
dependent inhibition of caspase-3 in HN2–5 cells. Caspase-
3 levels were assessed by enzyme assays (Fig. 2b), as well
as immunoblotting using the CM1 antibody (IDUN, CA),
which recognizes only the 17 kDa fragment of proteolyzed
and activated caspase-3 (Fig. 2c). We also asked if PKC was
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pathway. Although the broad-range PKC-inhibitor GFX
eliminated the BAY x 3702-elicited suppression of cas-
pase-3 (Fig. 2b and c), as shown Fig. 2a (lane 7), the same
concentration of GFX (2 AM) did not affect the BAY x
3702-evoked ERK1/2 activation. Therefore, our results
collectively show that, unlike PLCh, which is involved
upstream of ERK1/2, PKC is involved downstream of
ERK1/2 in the 5-HT1A agonist-triggered inhibition of cas-
pase-3 in HN2–5 cells.
3.2. Involvement of Ras and Raf-1 in serotonin 1A receptor-
mediated protection of HN2–5 cells against anoxia-
triggered apoptosis
Our previous studies had established that 5-HT1A recep-
tor-mediated activation of ERK1/2 is an obligate step in the
protection of HN2–5 cells from anoxia and reoxygenation
[11]. However, the link between the G protein-coupled, 5-
HT1A receptor and ERK1/2 was not clear. One possibility
was that the 5-HT1A receptor was connected to MEK and
ERK1/2 through the growth factor pathway, i.e. through Ras
and Raf-1. However, since direct activation of Raf-1
through phosphorylation by receptor-activated PKC (and
Ras-independent activation of ERK1/2, thereafter) has been
reported [20], we sought to test the involvement of Ras in
the 5-HT1A receptor-mediated protection of HN2–5 cells by
selectively inhibiting Ras and Raf-1 activity through tran-
sient expression of the corresponding dominant inhibitory
mutants, N17Ras and Raf301, respectively. By cotransfect-
ing pEGFP, which encodes a photoenhanced mutant of the
green fluorescent protein (GFP), approximately 60–80%
transfection efficiency was recorded. Additionally, it was
observed that transfection of a relatively large amount
(f 20 Ag/107 cells) of plasmid encoding N17Ras (pZip-
neoN17Ras) or Raf301 (pNMCRaf301) killed all cells
within 3–5 days. Both of these observations confirmed thatFig. 3. Involvement of components of the MAP kinase pathway, Ras and Raf-1, in
cells, transfected with (a) pZipneo or pZipneo-N17Ras or (b) pNMC or pNMC-Raf
3702) in the absence and presence of WAY100635 (1 AM), and then subjected to 6
and stained with HOECHST33342 to assess cell viability by fluorescence micros
with quadruplicate samples.the transfection efficiency was high enough for the record-
ing of a downstream effect after partially inhibiting Ras and
Raf-1 in the HN2–5 cells by using lower amounts (10 Ag)
of these plasmids.
Control transfection was achieved using the vectors
without the insert cDNAs (pZipneo and pNMC), and 10
Ag of each plasmid DNA along with 10 Ag of pEGFP were
transfected into 107 HN2–5 cells by electroporation. Our
assays were performed 96 h after transfection by electro-
poration at 220 V and 1000 AF in serum-free DMEM, when
the maximum recovery of cells was observed. Additionally,
the transfected and post-differentiation HN2–5 cells were
more fragile to anoxia and reoxygenation than the untrans-
fected but post-differentiation HN2–5 cells. Thus, in con-
trast to only 20–30% of apoptosis in the untransfected
HN2–5 cells, about 50–80% apoptosis was observed in
the transfected HN2–5 cells. In the control cells (transfected
with pZipneo and pNMC), apoptosis was inhibited in a
dose-dependent manner by BAY x 3702 (Fig. 3a and b).
This BAY x 3702-evoked protection was completely elim-
inated in the presence of either N17Ras (Fig. 3a) or Raf301
(Fig. 3b), thus confirming the involvement of Ras and Raf-1
in 5-HT1A agonist-evoked protection of anoxic HN2–5
cells.
3.3. A calcium-dependent PKC isozyme is involved in the
ERK1/2-mediated inhibition of caspase-3
Since agonist-stimulated PLCh activity results in IP3
synthesis, which eventually causes calcium release from
the ER, we postulated that intracellular calcium might
play an important role in the transmission of the ERK
signal to caspase-3. To test this hypothesis, we inves-
tigated if the PKC isozyme involved was either of the
calcium-sensitive molecules, PKCa or PKCh, by using a
selective inhibitor of PKCa and PKCh1 (Go¨6976, Cal-
biochem). It was observed that even as little as 1–5 nMserotonin 1A receptor-mediated protection of anoxic HN2–5 cells. HN2–5
-301, were differentiated and then treated with carrier or the agonist (BAY x
h hypoxia and 16 h reoxygenation. The cells were then fixed, permeabilized
copy. Data presented are the mean (F S.D.) of two experiments performed
                    
Fig. 5. Possible mechanisms of 5-HT1A receptor-mediated inhibition of
caspase-3.
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receptor-mediated inhibition of the anoxia-induced cas-
pase-3 activity, and this effect was observed using both 8-
OH-DPAT (Fig. 4a) as well as BAY x 3702 (Fig. 4b) as
agonist. Therefore, the 5-HT1A-R-mediated caspase-3
inhibition involved a calcium-dependent PKC, probably
PKCa or PKCh.
3.4. PKCa but not PKCb is stimulated downstream of
ERK1/2
Although the above experiments demonstrate that acti-
vation of a calcium-sensitive PKC is essential for the ERK1/
2-mediated inhibition of caspase-3, the suppression of
caspase-3 could still be due to synergistic action of the
activated forms of PKC and ERK1/2 (Fig. 5, mechanism 2).
In fact classical G protein coupled receptor pathways show
that stimulation of PLCh by the receptor-activated G protein
results in the production of diacylglycerol (DAG) by PLC-
catalyzed hydrolysis of phosphoinositide-bis-phosphate.
DAG is a potent activator of PKC. Thus, it was possible
that PKC was activated in a parallel pathway by the ligand-
bound 5-HT1A receptor. Following this, both PKC and
MAPK could act together in a synergistic manner on a
downstream target to finally cause inhibition of caspase-3
(Fig. 5, mechanism 2). Such synergism between activated
PKC and ERK1/2 would preclude activation of PKC by
ERK1/2.
The next experiment was designed to test the possibility
described above and also to identify the PKC isozyme
involved in this 5-HT1A-R-mediated caspase-3 inhibition.
To achieve this, we immunoprecipitated two typical, cal-
cium-dependent PKC isozymes, PKCa and PKCh, from the
lysates of 5-HT1A-agonist-stimulated and control HN2–5
cells. These immunoprecipitates were next tested for PKC
activity using a PKC-assay kit (Pierce) and an MBP peptide
as substrate. Agonist (8-OH-DPAT) stimulation of the cells
caused a dramatic stimulation of PKCa but not PKCh (Fig.
6). Moreover, this 5-HT1A agonist-evoked activation ofFig. 4. A calcium-dependent PKC isozyme is involved in the 5-HT1A receptor-m
HN2–5 cells were treated with (a) 8-OH-DPAT (1 AM) or (b) BAY x 3702 (1 AM)
Go. Results represent the mean (F S.D.) of two discrete experiments performedPKCa was eliminated in the presence of the selective
inhibitor of the MAPK pathway PD98059 (Fig. 6). Thus,
PKCa is likely to be the isozyme involved in the 5-HT1A-R-
mediated signaling to caspase-3. Also, PKC is not activated
in a parallel pathway; rather, it is downstream of the 5-
HT1A-R-ERK1/2 pathway, such that blocking ERK1/2 acti-
vation could eliminate the stimulation of PKCa (Fig. 5,
mechanism 1).ediated inhibition of caspase-3-like activity. (Go =Go¨6976). Differentiated
in the absence and presence of GFX (2 AM) or increasing concentrations of
with triplicate samples.
Fig. 6. A 5-HT1A agonist causes MAPK-dependent stimulation of PKCa
but not PKCh. Differentiated HN2–5 cells were treated with either PMA (1
AM) or 8-OH-DPAT (1 AM) in the absence and presence of PD98059 for 30
min. Next, the cells were lysed and PKCa and PKCh immunoprecipitated
successively from the lysates. The washed immunoprecipitates were
subjected to PKC enzyme assay. The experiment was carried out two
times with quadruplicate samples (*P< 0.0005).
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injury is also attenuated in 8-OH-DPAT-treated HN2–5
cells through a MAPK- and PKC-dependent pathway
The generality of this mechanism was tested by caus-
ing oxidative injury to the HN2–5 cells by the previously
used method of hydrogen peroxide treatment [26]. Initial
standardization showed that 500 AM H2O2 caused the
maximal increase in caspase-3 activity (Fig. 7a). Above
this H2O2 concentration, the cell membranes were rup-
tured causing caspase-3 and other soluble enzymes to
possibly leak out, thus yielding significantly lower cas-
pase-3 activity. Although there was a significant increase
in caspase-3 activity at 500 AM H2O2, the magnitude of
this increase depended on the confluency of the plates.
Nonetheless, further experiments showed that 8-OH-DPATFig. 7. Oxidative stress causes an increase in caspase-3, which is also reversed
Differentiated HN2–5 cells were treated with carrier or 8-OH-DPAT (1 AM) in th
PD98059 (25 AM) for 30 min. This was followed by addition of H2O2 from a sto
cells were incubated at 37 jC for 16 h and then lysed for caspase assay. Each ba
overall profile of caspase activity was observed in at least 10 independent experim
varied between two- and eight-fold of the carrier-treated cells.pretreatment of the differentiated HN2–5 cells attenua-
ted this caspase-3 activity by 40% (Fig. 7b). Also, this
caspase-3 inhibition was eliminated upon inhibition of the
MAPK pathway with PD98059 (PD), or inhibition of
PKC with GFX (Fig. 7b). Therefore, it is possible that 8-
OH-DPAT-evoked caspase-3 inhibition in anoxia/reoxyge-
nation as well as H2O2-treatment occurs through a ERK1/
2 and PKC-dependent pathway as shown in Fig. 5
(mechanism 1).
3.4. A kinase negative mutant of PKCa reverses the 5-HT1A
receptor-mediated blockage of H2O2-triggered caspase-3
activation
To confirm that the observed 8-OH-DPAT-evoked check
on the H2O2-triggered caspase-3 activation specifically
required PKCa, we performed transient expression of a
kinase-negative mutant of PKCa in the HN2–5 cells (Fig.
8). The GFP was cotransfected to identify the transfected
cells by fluorescence microscopy. After transfection, the
cells were differentiated as in the previous experiments and
then subjected to 200 AM H2O2 treatment for 16 h followed
by fixing of cells, and immunostaining using the same anti-
active caspase-3 (CM1) antibody as used for Western blot-
ting in an earlier experiment (Fig. 2c). Unlike the enzyme
assays for caspase-3 presented earlier, immunostaining does
not give a quantitative representation of caspase-3 activity.
So, the H2O2 concentration was adjusted to 200 AM (instead
of 500 AM) to obtain a greater number of cells at the initial
stages of caspase-3 activation. This procedure allowed us to
carry out an effective analysis of the effect of 8-OH-DPATon
caspase-3 activation in the HN2–5 cells. Representative
images show punctate anti-active caspase-3 staining (red)
in the perinuclear regions, which indicates proteolytic cleav-
age of caspase-3 following secretion of cytochrome c and
Apaf1 from the mitochondria (Fig. 8a). Flat cells withby a 5-HT1A agonist through a MAPK-, and PKC-dependent pathway.
e absence and presence of (a) WAY100635 (1 AM), or (b) GFX (2 AM), or
ck solution in serum-free DMEM to the indicated concentrations. Next, the
r presented is the mean (F S.D.) of triplicate samples. Although the same
ents, the magnitude of 0.5 mM H2O2-evoked activation of caspase activity
Fig. 8. The 8-OH-DPAT evoked inhibition of caspase-3 is reversed in the presence of a kinase negative mutant (KN) of PKCa. HN2–5 cells grown in duplicate
wells were cotransfected with pEGFP in the presence of either SRDpkca(KN) (expressing kinase negative PKCa) or SRDpkcaWT (expressing wild-type
PKCa). A control set of cells received pEGFP alone. Transfected cells were differentiated and then treated with 200 AM H2O2 for 16 h followed by fixing and
staining with anti-active caspase-3 antibody (CM1) and an Alexa Fluor 568-labeled 2j antibody (red staining). Activation of caspase-3 was assessed from the
proportion of GFP cells (green) that also showed red staining. (a) Representative images show punctate anti-active caspase-3 staining (red) in the perinuclear
regions, which indicates proteolytic cleavage of caspase-3. Reduced caspase-3 activity appears as low-intensity, diffused, red color. (b) Data obtained represent
three independent experiments, each performed with duplicate wells in which cells were counted in six fields. In the three experiments, the 8-OH-DPAT-evoked
decrease in anti-active caspase-3 stained cells varied between 30% and 50% of carrier-treated in the GFP- and pkcaWT-transfected cells.
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red staining were considered to be negative in terms of
caspase-3 activation. It should be noted from our caspase-3
assays that caspase-3 activation is inhibited but not com-
pletely eliminated in the presence of 8-OH-DPAT. While
cells transfected with GFP alone or GFP plus SRDpkcaWT
showed the expected inhibition of CM1 antibody staining
upon 8-OH-DPAT pretreatment (red), cells cotransfected
with the kinase-negative mutant of PKCa (SRDpkcaKN)showed complete reversal of this 8-OH-DPAT-evoked
attenuation of anti-active caspase-3 staining (Fig. 8b). Such
elimination of 8-OH-DPAT-evoked suppression of caspase-3
was also observed in cells pretreated with the MEK inhibitor
PD98059. Data obtained from this study and that shown in
Fig. 7 confirmed that the general, 5-HT1A-R-mediated pro-
tective pathway observed in the HN2–5 cells indeed
involved PKCa downstream of ERK1/2 as proposed earlier
in Fig. 5 (mechanism 1).
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Apoptosis is an important event that is essential for
embryonic development as well as efficient removal of
irreversibly damaged cells. This signaling program has been
studied extensively in blood cells, and as a result, major
biochemical mechanisms for the apoptotic program have
been established. Simultaneously, research on growth fac-
tors have revealed the existence of a receptor tyrosine
kinase-activated PI-3K pathway, which eventually causes
inhibition of this apoptotic programming, such that some the
partially injured cells can be revived [15,16]. This is
particularly important in the central nervous system, since,
typically, after a stroke or neuronal injury caused by other
insults, delayed death of a large number of neurons is
observed, which often results in the loss of cognitive and
motor functions. Additionally, during embryonic develop-
ment, a large number of pre-neuronal cells undergo apop-
tosis to promote survival of neurons that have already made
synaptic connections. Beneficial effects of apoptosis are also
observed when chemotherapeutic agents eliminate cancer
cells.
Receptor-mediated regulation of apoptosis could serve as
an effective way of protecting brain neurons after a stroke or
brain injury. As is true for the PI-3 kinase pathway, the MAP
kinase cascade, which is stimulated by the growth factor
receptors, is also linked to the protection of various cell
types against apoptosis. Intriguingly, the isoforms ERK1/2
and p38 of MAPK that are stimulated at the end of the
MAPK pathway have been linked to the inhibition and
promotion of apoptosis, respectively [27]. Although earlier
studies have demonstrated the importance of the MAPK
pathway in protection against apoptosis [27,28], molecular
events connecting this pathway to apoptosis are not clear.
Results presented here provide a direct demonstration of
MAPK-dependent inhibition of an enzyme, caspase-3,
which actually causes the signature cytoskeletal breakdown
that defines apoptosis.
Our studies in the hippocampal neuron-derived cell line
HN2–5 has revealed a novel link between the 5-HT1A
receptor and the proapoptotic enzyme caspase-3 through
the important enzyme PKCa. It had been reported by
multiple research teams that inhibition of PKC with either
staurosporine or PKCa-targeted ribozyme causes apoptosis
[29,30]. If PKCa is indeed a downstream target of ERK1/2,
then the activity of this protein should be regulated by
ERK1/2. Our immunoprecipitation experiments confirm
that 8-OH-DPAT treatment of HN2–5 cells indeed causes
activation of PKCa via ERK1/2 (Fig. 6). If this occurs by
direct ERK1/2-catalyzed phosphorylation of PKC, then the
particular PKC isozyme involved should have one or more
consensus ERK1/2 phosphorylation sites. Earlier studies
have revealed that the PKCa molecule is phosphorylated
at Thr497, Thr638, and S657 residues. Following activation by
membrane attachment, these phosphate groups are removed
by a PKCa-activated phosphatase and the dephosphorylatedPKCa is rapidly degraded [31]. Thus phosphorylation is
important for proper activation and turnover of the PKCa
molecule. Of these phosphorylation sites, the Thr638 residue
is within a MAPK recognition sequence. Therefore, it is
possible that the PKCa molecule is regulated by ERK1/2
through direct phosphorylation.
The mechanism of PKCa mediated caspase-3 inhibition
also requires further analysis. Earlier studies have shown
that drugs which activate PKC promote cell survival [32],
and inhibitors of PKC, such as staurosporin, induce apop-
tosis [29,33,34]. It has also been observed that activators of
PKC stimulate phosphorylation of Bad at serine 112,
indirectly, through a downstream target, p90RSK [35]. Al-
though each of Bad, caspase-9 and caspase-3 harbors one or
more copies of the PKC phosphorylation sequence (S/TXR/
K), recent studies have shown that a PKC substrate, p90RSK,
actually catalyzes PKC-dependent phosphorylation of Bad
at Ser112, which ablates interactions of Bad with Bcl-2, thus
blocking apoptosis [35,36]. Therefore, phosphorylation of
Bad, caspase-3 or caspase-9 could be a reason for the inhi-
bition of caspase-3.
Caspases are kept under check in some viruses that
harbor genes encoding caspase inhibitory proteins. In this
way, such viruses suppress host defense mechanisms that
otherwise would eliminate virus-infected cells by apoptosis.
The first inhibitor of apoptosis protein (IAP) was discovered
in baculoviruses [37]. Subsequently, cellular IAP homologs
were found in many animal species [38,39]. Each IAP
molecule contains one to three copies of an 80-amino acid
baculovirus IAP repeat (BIR), which are potentially
involved in Zn2 + ion coordination via a DX3CX2C/HX6C
consensus [40]. Additionally, BIR proteins also contain a
C3HC4 RING finger [39]. Mammalian IAP proteins (XIAP,
NAIP, cIAP1, cIAP2, and survivin) block apoptosis by
inactivating the terminal effector caspases caspase-3 and -7
and by interfering with upstream activation of caspase-9
[39,41,42].
A likely mechanism of inhibition of caspase-3 involves
NFnB mediated induction of IAP expression. Cowen et al.
[43] have shown that agonist activation of the 5-HT1A-R
causes activation of NFnB. Also, it has been reported that
PKC activation could cause stimulation of the transcription
factor NFnB, which in turn causes induced expression of the
IAPs [44,45]. As discussed earlier, the IAPs are known to
block caspase-3 activity and apoptosis. Therefore, it is
possible that a 5-HT1A-R-mediated NFnB activation causes
induced expression of IAPs, thereby resulting in an inhib-
ition of caspase-3.
There has been a considerable debate over the molecular
signals that relay the effect of any receptor-mediated
increase in intracellular calcium ([Ca2 +]i) to the MAPK
pathway in various cell types (Fig. 5). Our earlier studies
had implicated [Ca2 +]i in the 5-HT1A-R!MAPK signaling
in HN2–5 cells [11]. Other reports in diverse cell types have
shown the involvement of the calcium-sensitive signaling
molecules like Src and Pyk2 in receptor-mediated MAPK
T. Adayev et al. / Biochimica et Biophysica Acta 1640 (2003) 85–96 95signaling [9,46]. Our investigations to complete this link
between the 5-HT1A-R-mediated increase in [Ca
2 +]i and the
MAPK pathway in the HN2–5 cells will be reported else-
where.
We have demonstrated that the 5-HT1A receptor-mediated
blockage of insult-triggered caspase-3 activation requires
PKCa. Collectively, this study elucidates a novel, neuro-
protective pathway, 5-HT1A-R!G protein! PLCh!
Ca2 +!!!MAPK! PKCa! caspase-3 (inhibition),
placing PKCa in a novel role as a signaling molecule lin-
king the MAPK pathway to caspase-3. Selective activation
of PKCa over PKCh in the HN2–5 cells indicates that
specific PKC molecules are sequestered in the cytosol as a
sequel to agonist activation of a receptor. Current literature
is replete with examples of such channeled transmission of
molecular signals in the neural and other cell types. Further
investigation of this pathway would reveal new mecha-
nisms and proteins linking G protein-coupled receptors to
ERK1/2 activation and caspase-3 inhibition in neuronal
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